C

Central Research Associates | Birmingham, AL

Research site
(Unclaimed)
Location
2660 10th Avenue South, Building 1, Suite 735, Birmingham, Alabama, United States of America

Site insights

Top conditions

Top treatments

Linaclotide
Lasmiditan
LY573144
MK-0616
Olezarsen
Secukinumab
Retatrutide
BOS-580
Vilaprisan
Levothyroxine

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

13 of 16 total trials
Locations recently updated

A 12-Month Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine (PIONEER-PEDS2)

The reason for this 12-month, open-label study is to see if the study drug lasmiditan is safe and effective for the intermittent acute treatment of m...

Enrolling
Migraine
Drug: Lasmiditan

The purpose of this study is to evaluate the safety, tolerability, and immunogenicity of V116 compared to PPSV23 in children 2 through 17 years of ag...

Enrolling
Pneumococcal Infection
Biological: V116
Biological: PPSV23

This is a safety study to evaluate BOS-580 administered subcutaneously over 12 weeks in Part A or 24 weeks in Part B.

Active, not recruiting
Nonalcoholic Steatohepatitis (NASH)
Drug: BOS-580
Drug: Placebo
Locations recently updated

The reason for this study is to see if lasmiditan is safe and effective in children aged 6 to 17 with migraine. The study will last up to 20 weeks an...

Enrolling
Migraine
Drug: Placebo
Drug: Lasmiditan

The main purposes of Part A of this study are to evaluate the safety, tolerability, and immunogenicity of mRNA-1345 coadministered with a seasonal in...

Active, not recruiting
Respiratory Syncytial Virus
Biological: mRNA-1273.214
Biological: mRNA-1345

The purpose of this study is to evaluate the efficacy of olezarsen as compared to placebo on the percent change in fasting triglycerides (TG) from ba...

Enrolling
Severe Hypertriglyceridemia
Drug: Olezarsen
Drug: Placebo
Locations recently updated

This study will evaluate the efficacy and safety of Armour Thyroid treatment compared with synthetic T4 in subjects who have primary hypothyroidism a...

Enrolling
Hypothyroidism
Drug: Levothyroxine
Drug: Armour Thyroid

The study was performed to assess the efficacy and safety of Vilaprisan in subjects with uterine fibroids compared to standard of care

Active, not recruiting
Uterine Fibroids
Drug: Vilaprisan (BAY1002670)
Other: Standard of care

This is a Phase 3 trial to evaluate the BP-lowering effect of lorundrostat (an aldosterone synthase inhibitor) in subjects with uncontrolled and resi...

Enrolling
Hypertension
Drug: Placebo
Drug: lorundrostat Dose 2
Status recently updated

LIN-MD-66 is a Phase 3 open-label study with 24 weeks (Functional Constipation participants) or 52 weeks (Irritable bowel syndrome with constipation...

Invitation-only
Active, not recruiting
Functional Constipation
Irritable Bowel Syndrome With Constipation
Drug: Functional Constipation (FC) participants (LIN-MD-62 and LIN-MD-64 completers)
Drug: Irritable Bowel Syndrome with Constipation (IBS-C) participants (LIN-MD-63 completers)
Locations recently updated

This is a phase 3, randomized, placebo-controlled study of the efficacy and safety of MK-0616, an oral proprotein convertase subtilisin/kexin type 9...

Enrolling
Arteriosclerosis
Hypercholesterolaemia
Drug: Placebo
Drug: MK-0616

The purpose of the present study is to assess the efficacy of secukinumab 300 mg s.c. (subcutaneous) compared to placebo, each in combination with st...

Active, not recruiting
Rotator Cuff Tendinopathy
Drug: Secukinumab
Drug: Placebo

The main purpose of this study is to determine if retatrutide can significantly lower the incidence of serious heart-related complications or prevent...

Enrolling
Overweight and Obesity
Drug: Retatrutide
Drug: Placebo

Trial sponsors

Merck Sharp & Dohme (MSD) logo
AbbVie logo
Lilly logo
Bayer logo
Boston Scientific logo
Ionis Pharmaceuticals logo
M
Moderna logo
Novartis logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems